CSPC Pharmaceutical (HKG:1093) obtained approval from the U.S. Food and Drug Administration to conduct clinical trials of JMT206 in the US, a Wednesday filing with the Hong Kong bourse said.
The indication for the trial approval is weight management for individuals who are overweight, or have obesity, or at least one weight-related comorbidity.
The pharmaceutical firm had obtained approval for trials in China from the National Medical Products Administration in November.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments